Anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study (ALTER-GO-010) 报告时间:2024年3月17日 7:45 AM-9:00 AM(北京时间)
Anlotinib plus penpulimab plus chemo-less therapy in first-line treatment for persistent, recurrent, or metastatic cervical cancer: A single-arm, phase II study (ALTN-AK105-II-06) The efficacy and safety of combining anlotinib with albumin-bound paclitaxel and cisplatin in patients with recurrent advanced cervical cancer: A prospective single-arm, open-label, phase II trial A prospective, single-arm, open-label, phase II clinical trial on efficacy and safety of cadonilimab plus anlotinib for recurrent, metastatic or persistent cervical cancer Real world data of anlotinib for gynecological tumors with liver metastases in China SGO官网已公布本届会议入选研究题目,您可登录如下网址查看:
https://www.sgo.org/events/annual-meeting/
* 本资料为专业医学资料,旨在促进医药信息的沟通和交流,仅供医疗卫生专业人士参考;任何处方请参考产品最新详细处方资料